NO20020222L - Oralt aktive androgener - Google Patents

Oralt aktive androgener

Info

Publication number
NO20020222L
NO20020222L NO20020222A NO20020222A NO20020222L NO 20020222 L NO20020222 L NO 20020222L NO 20020222 A NO20020222 A NO 20020222A NO 20020222 A NO20020222 A NO 20020222A NO 20020222 L NO20020222 L NO 20020222L
Authority
NO
Norway
Prior art keywords
orally active
active androgens
androgens
orally
active
Prior art date
Application number
NO20020222A
Other languages
English (en)
Other versions
NO20020222D0 (no
Inventor
Hubert Jan Jozef Loozen
Dirk Leysen
Jaap Van Der Louw
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of NO20020222D0 publication Critical patent/NO20020222D0/no
Publication of NO20020222L publication Critical patent/NO20020222L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0074—Esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20020222A 1999-07-16 2002-01-15 Oralt aktive androgener NO20020222L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99202348 1999-07-16
PCT/EP2000/006544 WO2001005806A1 (en) 1999-07-16 2000-07-10 Orally active androgens

Publications (2)

Publication Number Publication Date
NO20020222D0 NO20020222D0 (no) 2002-01-15
NO20020222L true NO20020222L (no) 2002-01-25

Family

ID=8240463

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20020222A NO20020222L (no) 1999-07-16 2002-01-15 Oralt aktive androgener

Country Status (28)

Country Link
US (3) US6313108B1 (no)
EP (1) EP1203011B1 (no)
JP (1) JP2003505394A (no)
KR (1) KR20020092890A (no)
CN (1) CN1360589A (no)
AR (1) AR024746A1 (no)
AT (1) ATE257159T1 (no)
AU (1) AU770412B2 (no)
BR (1) BR0012489A (no)
CA (1) CA2379223A1 (no)
CO (1) CO5200765A1 (no)
CZ (1) CZ2002192A3 (no)
DE (1) DE60007530T2 (no)
ES (1) ES2213596T3 (no)
HK (1) HK1043797A1 (no)
HU (1) HUP0201952A3 (no)
IL (1) IL147332A0 (no)
MX (1) MXPA02000601A (no)
NO (1) NO20020222L (no)
NZ (1) NZ516525A (no)
PE (1) PE20010330A1 (no)
PL (1) PL353007A1 (no)
RU (1) RU2002103883A (no)
SK (1) SK712002A3 (no)
TR (1) TR200200076T2 (no)
TW (1) TW548277B (no)
WO (1) WO2001005806A1 (no)
ZA (1) ZA200200106B (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2204613T3 (es) * 1999-04-06 2004-05-01 Akzo Nobel N.V. Androgenos 7-alfa alquilo oralmente activos.
AU4966101A (en) * 2000-03-31 2001-10-15 Us Gov Health & Human Serv Methods of making and using 7alpha,11beta-dimethyl-17beta-hydroxy-4-estren-3-one17beta-trans-4-m-butylcyclohexane carboxylate and 7alpha,11beta-dimethyl-17beta -hydroxyestr-4-en-3-one 17-undecanoate
US20030069215A1 (en) * 2001-03-30 2003-04-10 The Government Of The United States Of America, Methods of making and using 7a,11b-dimethyl-17b-hydroxy-4-estren-3-one 17b-trans-4-n-butylcyclohexane carboxylate and 7a,11b-dimethyl-17b-hydroxyestr-4-en-3-one 17-undecanoate
BR0112791A (pt) * 2000-07-28 2003-06-24 Akzo Nobel Nv Composto esteroidal 16alfa-substituido, uso do mesmo, métodos de tratamento para ativação seletiva de receptores de estrogênio do subtipo alfa, e para terapia de reposição hormonal ou contracepção, e, composição farmacêutica
ES2261665T3 (es) * 2001-03-30 2006-11-16 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Procedimientos de fabricacion y formulaciones farmaceuticas que comprenden 7alfa, 11beta-dimetil-17beta-hidroxiestra-4, 14-dien-3-ona y 17-esteres del mismo.
DE60330749D1 (de) * 2002-01-21 2010-02-11 Organon Nv Verfahren zur herstellung von 7-alpha-methylsteroide
GB0304927D0 (en) * 2003-03-04 2003-04-09 Resolution Chemicals Ltd Process for the production of tibolone
PE20050677A1 (es) 2003-12-22 2005-10-04 Akzo Nobel Nv Esteroides con perfil androgenico y progestagenico mixto
UA89964C2 (ru) 2004-09-08 2010-03-25 Н.В. Органон 15β-ЗАМЕЩЕННЫЕ СТЕРОИДЫ, КОТОРЫЕ ИМЕЮТ СЕЛЕКТИВНУЮ ЭСТРОГЕННУЮ АКТИВНОСТЬ
CN102227441A (zh) * 2008-10-15 2011-10-26 斯索恩有限公司 制备氟维司群的方法和中间体
WO2012164095A1 (en) * 2011-06-01 2012-12-06 Estetra S.A. Process for the production of estetrol intermediates
SG195118A1 (en) 2011-06-01 2013-12-30 Estetra S A Process for the production of estetrol intermediates
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
SG11201401282PA (en) * 2011-10-07 2014-05-29 Estetra Sprl Process for the production of estetrol
WO2015181116A1 (en) 2014-05-26 2015-12-03 Crystal Pharma, S.A.U. Process and intermediades for the preparation of 7-alkylated steroids
SI3310346T1 (sl) 2015-06-18 2021-07-30 Estetra Sprl Orodisperzibilna tableta, ki vsebuje estetrol
US10894014B2 (en) 2015-06-18 2021-01-19 Estetra Sprl Orodispersible tablet containing Estetrol
PE20231714A1 (es) 2015-06-18 2023-10-23 Estetra Sprl Unidad de dosificacion orodispersable que contiene un componente estetrol
UA123098C2 (uk) 2015-06-18 2021-02-17 Естетра Спрл Диспергована у порожнині рота одиниця дозування, що містить естетрольний компонент
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
ES2906117T3 (es) * 2017-02-23 2022-04-13 Siemens Healthcare Diagnostics Inc Conjugados de androstenodiona quimioluminiscente
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA712312B (en) * 1970-04-28 1972-01-26 Ochsner Med Found Alton 4,14-estradiene compounds

Also Published As

Publication number Publication date
CO5200765A1 (es) 2002-09-27
EP1203011B1 (en) 2004-01-02
DE60007530D1 (de) 2004-02-05
ATE257159T1 (de) 2004-01-15
KR20020092890A (ko) 2002-12-12
TR200200076T2 (tr) 2002-04-22
ZA200200106B (en) 2003-06-25
BR0012489A (pt) 2002-04-02
PE20010330A1 (es) 2001-03-22
US6313108B1 (en) 2001-11-06
US6780854B2 (en) 2004-08-24
NZ516525A (en) 2003-06-30
AU770412B2 (en) 2004-02-19
JP2003505394A (ja) 2003-02-12
MXPA02000601A (es) 2002-07-30
IL147332A0 (en) 2002-08-14
US6541465B2 (en) 2003-04-01
ES2213596T3 (es) 2004-09-01
DE60007530T2 (de) 2004-12-23
HK1043797A1 (zh) 2002-09-27
CZ2002192A3 (cs) 2002-06-12
WO2001005806A1 (en) 2001-01-25
AR024746A1 (es) 2002-10-23
SK712002A3 (en) 2002-06-04
RU2002103883A (ru) 2004-02-27
TW548277B (en) 2003-08-21
PL353007A1 (en) 2003-09-22
HUP0201952A3 (en) 2003-10-28
US20020022609A1 (en) 2002-02-21
US20030087886A1 (en) 2003-05-08
NO20020222D0 (no) 2002-01-15
AU6562900A (en) 2001-02-05
EP1203011A1 (en) 2002-05-08
CN1360589A (zh) 2002-07-24
HUP0201952A2 (en) 2002-10-28
CA2379223A1 (en) 2001-01-25

Similar Documents

Publication Publication Date Title
NO20020222L (no) Oralt aktive androgener
PT1220856E (pt) Compostos farmaceuticamente activos
IS5568A (is) Lyfjafræðilega virkt morfólínól
DK1181017T3 (da) Metalloproteaseinhibitorer
NO2010019I2 (no) 6-per-deoksy-6-per-(2-karboksetyl)tio-y-cyklodextrin
FI4231U1 (fi) Kotelo
DE60035580D1 (de) Halbleiter
DE60043730D1 (de) Arylsulfonamid-substituierte hydroxamsäure-derivate
DE60032425D1 (de) Ätzvorrichtung
DK1237904T3 (da) 14,15-beta-methylensubstituerede androgener
DE60039349D1 (de) Elektrochemischer kondensator
DE59902159D1 (de) Aktiver mikromischer
DK1218127T3 (da) Støbevalse
DE60018144D1 (de) Wälzelement
ITMI991742A0 (it) Bisplatino complessi attivi per via orale
DE60010809D1 (de) Entwicklungsgerät
ZA200204604B (en) Saccharin derivatives as orally active elastase inhibitors.
DE50012367D1 (de) Abrollmaschine
DE60004561D1 (de) Aktive baugruppe
ID27139A (id) Bertukol kusmargono
SE9901854D0 (sv) New pharmaceutically active compounds
IS8740A (is) Lyfjafræðilega virkt morfólínól
SE0000645D0 (sv) New pharmaceutically active compounds
ATA9099A (de) Badewanneneinstiegshilfe
SE9802539D0 (sv) New pharmaceutically active compounds

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application